RATIONALE: IkappaB kinase (IKK) activates NF-kappaB which plays a pivotal role in pro-inflammatory response in the lung. NF-kappaB has been shown to be activated in alveolar macrophages and peripheral lungs of smokers and patients with chronic obstructive pulmonary disease. We investigated the anti-inflammatory effect of a highly selective and novel IKKbeta/IKK2 inhibitor, PHA-408 [8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[gamma]indazole-3-carboxamide], in lungs of rat in vivo. METHODS: Adult Sprague-Dawley rats were administered orally with PHA-408 (15 and 45 mg/kg) daily for 3 days and exposed to LPS aerosol (once on day 3, 2 h post-last PHA-408 administration) or cigarette smoke (CS; 2h after PHA-408 administration for 3 days). Animals were sacrificed at 1, 4 and 24 h after the last exposure, and lung inflammatory response and NF-kappaB activation were measured. RESULTS: Oral administration of IKKbeta/IKK2 inhibitor PHA-408 significantly inhibited LPS- and CS-mediated neutrophil influx in bronchoalveolar lavage (BAL) fluid of rats. The levels of pro-inflammatory mediators in BAL fluid (CINC-1) and lungs (IL-6, TNF-alpha, IL-1beta and GM-CSF) were also reduced by PHA-408 administration in response to LPS or CS exposures. The reduced pro-inflammatory response in PHA-408-administered rats was associated with decreased nuclear translocation and DNA binding activity of NF-kappaB in response to LPS or CS. CONCLUSION: These results suggest that IKKbeta/IKK2 inhibitor PHA-408 is a powerful anti-inflammatory agent against LPS- and CS-mediated lung inflammation. Copyright 2010 Elsevier Ltd. All rights reserved.
RATIONALE: IkappaB kinase (IKK) activates NF-kappaB which plays a pivotal role in pro-inflammatory response in the lung. NF-kappaB has been shown to be activated in alveolar macrophages and peripheral lungs of smokers and patients with chronic obstructive pulmonary disease. We investigated the anti-inflammatory effect of a highly selective and novel IKKbeta/IKK2 inhibitor, PHA-408 [8-(5-chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[gamma]indazole-3-carboxamide], in lungs of rat in vivo. METHODS: Adult Sprague-Dawley rats were administered orally with PHA-408 (15 and 45 mg/kg) daily for 3 days and exposed to LPS aerosol (once on day 3, 2 h post-last PHA-408 administration) or cigarette smoke (CS; 2h after PHA-408 administration for 3 days). Animals were sacrificed at 1, 4 and 24 h after the last exposure, and lung inflammatory response and NF-kappaB activation were measured. RESULTS: Oral administration of IKKbeta/IKK2 inhibitor PHA-408 significantly inhibited LPS- and CS-mediated neutrophil influx in bronchoalveolar lavage (BAL) fluid of rats. The levels of pro-inflammatory mediators in BAL fluid (CINC-1) and lungs (IL-6, TNF-alpha, IL-1beta and GM-CSF) were also reduced by PHA-408 administration in response to LPS or CS exposures. The reduced pro-inflammatory response in PHA-408-administered rats was associated with decreased nuclear translocation and DNA binding activity of NF-kappaB in response to LPS or CS. CONCLUSION: These results suggest that IKKbeta/IKK2 inhibitor PHA-408 is a powerful anti-inflammatory agent against LPS- and CS-mediated lung inflammation. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: A Di Stefano; G Caramori; T Oates; A Capelli; M Lusuardi; I Gnemmi; F Ioli; K F Chung; C F Donner; P J Barnes; I M Adcock Journal: Eur Respir J Date: 2002-09 Impact factor: 16.671
Authors: Raminder Aul; Jane Armstrong; Annelyse Duvoix; David Lomas; Brian Hayes; Bruce E Miller; Chris Jagger; Dave Singh Journal: Br J Clin Pharmacol Date: 2012-12 Impact factor: 4.335
Authors: Alexander S Antonov; Galina N Antonova; David H Munn; Nahid Mivechi; Rudolf Lucas; John D Catravas; Alexander D Verin Journal: J Cell Physiol Date: 2011-02 Impact factor: 6.384
Authors: David H McMillan; Carolyn J Baglole; Thomas H Thatcher; Sanjay Maggirwar; Patricia J Sime; Richard P Phipps Journal: Am J Pathol Date: 2011-05-05 Impact factor: 4.307
Authors: Hongwei Yao; Sangwoon Chung; Jae-woong Hwang; Saravanan Rajendrasozhan; Isaac K Sundar; David A Dean; Michael W McBurney; Leonard Guarente; Wei Gu; Mikko Rönty; Vuokko L Kinnula; Irfan Rahman Journal: J Clin Invest Date: 2012-05-01 Impact factor: 14.808
Authors: Sang Yeub Lee; Marina Miller; Jae Youn Cho; Dae Jin Song; Michael Karin; David H Broide Journal: Int Immunopharmacol Date: 2010-05-18 Impact factor: 4.932